Ipsen successfully issues inaugural €300 million 7-year Notes


Ipsen has been able to take advantage of the current market environment to raise long-term financing at attractive conditions. The transaction was well received by a diversified investor base and was more than 4 times over-subscribed, demonstrating the market’s confidence in Ipsen’s long-term business model.

The purpose of this issue is to diversify and extend the maturity of Ipsen’s financial resources and to support its investment and business development strategy.

BNP Paribas, HSBC Bank plc, and Société Générale were Global Coordinators and Joint Lead Managers. Crédit Agricole Corporate and Investment Bank and Natixis also acted as Joint Lead Managers.

About the Notes:
Issuer: Ipsen S.A.
Amount: €300 million
Coupon: 1.875%
Maturity: 7 years
Market: Euronext Paris (Regulated Market)


© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022